Full-Time

Assoc Prin. Scientist

Analytical R&D

Confirmed live in the last 24 hours

Merck

Merck

10,001+ employees

Develops medicines and vaccines for health issues

Biotechnology
Healthcare

Compensation Overview

$139.6k - $219.7kAnnually

+ Bonus + Long Term Incentive

Senior, Expert

Linden, NJ, USA

Hybrid work model requiring three days on-site per week.

Category
Lab & Research
Life Sciences
Medical Research
Required Skills
Data Analysis

You match the following Merck's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • B.S. in Chemistry, Biochemistry, Engineering, Pharmaceutical Sciences, or related field with 10 years of relevant experience; or Master's degree with 7 years of relevant experience; or Ph.D. with 3 years of relevant experience.
  • Strong background and experience in separations science
  • Extensive experience with UPLC/HPLC analysis of biologics (e.g. SEC, RP, IEX) and/or experience with capillary electrophoresis (CE) analysis of biologics (e.g. CE-SDS, iCIEF)
  • Extensive experience with process- and impurity-related residual assay development using molecular biology and immunoassay techniques.
  • Background in Analytical Methodologies and sound scientific understanding of Critical Quality Attributes/QbD/DOE principles as well as data analysis and statistics for setting specifications.
  • Ability to design, execute and/or direct the development and qualification of release, characterization, and stability assays for testing of clinical trial material and in support of product and process development.
  • A strong team player with excellent oral and written communication skills; ability to work both independently for development of assays and cross-functionally for successful transfer of assays.
  • Accurately and efficiently documentation of experiments
  • Strong ability to deliver complex objectives under aggressive timelines in a rapidly changing environment.
Responsibilities
  • Development, qualification, implementation, troubleshooting and transfer of analytical methods for monoclonal proteins or other complex therapeutic proteins.
  • Development of new assay platforms, benchmarking current approaches/techniques to industry standards, and providing technical leadership of design of experiments and data interpretation.
  • Authoring and reviewing internal technical reports, sections of regulatory filings (e.g., IND, BLA) and external scientific publications.
Desired Qualifications
  • Understanding of protein degradation mechanisms and link between analytical methodologies for analysis.
  • Experience with qualification, validation, and transfer of assays to a GLP or regulated laboratory environment as listed in ICH Q2 and USP<1033>.
  • Experience in representing analytical functional area on project teams.
  • Experience with complex glycan analysis and link to mechanisms of actions.
  • Experience in analysis of various Biologic modalities (e.g., mAb, antibody-drug conjugate, fusion protein)
  • Experience in data analytics, programming, or laboratory automation.

Merck develops medicines and vaccines to address significant health challenges such as cardiovascular disease, diabetes, and cancer. The company conducts extensive research and development to create new treatments, focusing on the pharmaceutical and biotechnology sectors. Merck generates revenue through the sale of prescription medications, vaccines, and animal health products. A key aspect of Merck's approach is its commitment to patient assistance programs, which provide free medicines and vaccines to eligible patients, as well as professional resources through platforms like Merck Connect and Merck Manuals. What sets Merck apart from its competitors is its strong emphasis on scientific research and its diverse range of healthcare solutions aimed at improving global health.

Company Size

10,001+

Company Stage

IPO

Total Funding

$347.4M

Headquarters

Kenilworth, Illinois

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck's investment in AI-driven healthtech enhances its capabilities in digital healthcare.
  • The partnership with Atropos Health accelerates real-world evidence generation for rapid insights.
  • Merck's high dividend yield makes it attractive to income-focused investors.

What critics are saying

  • Increased competition in oncology could impact Merck's market share.
  • Integration of WuXi Vaccines' facility may pose operational challenges.
  • Data privacy issues may arise from the collaboration with Atropos Health.

What makes Merck unique

  • Merck focuses on innovative medicines for cardiovascular, diabetes, and cancer treatments.
  • The company offers patient assistance programs providing free medicines to qualified patients.
  • Merck's extensive R&D efforts drive the development of new treatments and therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Holidays

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Flexible Work Hours

Company News

MarketBeat
Feb 15th, 2025
Accretive Wealth Partners LLC Makes New $531,000 Investment in Merck & Co., Inc. (NYSE:MRK)

Accretive Wealth Partners LLC makes new $531,000 Investment in Merck & Co., Inc. (NYSE:MRK).

Tech in Asia
Feb 13th, 2025
HD raises $7.8M from MSD

Thai healthtech startup HD has secured $7.8 million in equity funding from US pharmaceutical giant Merck Sharp & Dohme, marking MSD's first investment in Asia-Pacific healthtech. Other investors include SBI Ven Capital, M Venture Partners, FEBE Venture, and Partech Partners. HD plans to use the funds to enhance its AI capabilities and expand its marketplace. Since its founding, HD has onboarded 2,500 hospitals and clinics, offering 30,000 services to over 400,000 customers in Thailand and Indonesia.

Labiotech
Feb 4th, 2025
Word Cancer Day: Trends In Cancer Therapeutics To Look Forward To In 2025

Newsletter Signup - Under Article / In Page"*" indicates required fields Cancer has long been one of the most persistent and deadly diseases, and with its ability to evolve, resist treatment, and spread relentlessly, it has left scientists grappling for solutions. Yet, amid the uncertainty, the landscape of cancer treatments is shifting. Once limited to chemotherapy and radiation, treatment options have expanded since and continue to do so. Largely thanks to this, cancer death rates have fallen by 33% in the U.S. since 1991. As we observe World Cancer Day today, let us look at some of the trends in oncology expected to improve cancer care in 2025.While the number of clinical trials for cancer has been growing, they have been moving towards “innovative designs and patient-centric approaches,” according to Stephan Schann, chief scientific officer of French biotech Domain Therapeutics.“The industry has witnessed increased investment in platforms that address previously ‘undruggable’ targets and I expect this theme to continue into 2025

Labiotech
Jan 31st, 2025
U.K. Biotech Defies The Odds, Raising £3.5B In 2024

Newsletter Signup - Under Article / In Page"*" indicates required fields The past year has been one of ups and downs for the biotech and healthcare sectors in the U.K. A report by the UK BioIndustry Association (BIA) revealed how investments played a part in research and development (RD) in the country. Equity financing was at quite a high last year. Around £3.5 billion ($4.36 million) was raised by the industry – a 94% increase from 2023. This highlights “renewed confidence and the resilience of the U.K. biotech industry,” according to Steve Bates, chief executive officer (CEO) of BIA.“This year’s figures demonstrate that biotech is a vibrant growth sector of the U.K. economy with an exceptional ability to attract global investment

Insider Monkey
Jan 22nd, 2025
Here's Why Merck & Co., Inc. (MRK) Is Among the Highest Yielding Dividend Stocks In the Dow

Here's why Merck & Co., Inc. (MRK) is among the Highest Yielding Dividend Stocks in the Dow.